Cue Biopharma, Inc. (CUE) - Q1 2025 Filing Summary
Business Context and Reporting Period
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics (Immuno-STAT platform) to selectively modulate disease-specific T cells for autoimmune diseases and cancer. This Form 10-Q covers the quarterly period ended March 31, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Collaboration Revenue | $421 | $1,717 |
| Total Operating Expenses | $12,720 | $14,385 |
| Net Loss | $(12,257) | $(12,347) |
| Net Loss Per Share (Basic & Diluted) | $(0.17) | $(0.25) |
| Cash and Cash Equivalents (End of Period) | $13,136 | $22,459 |
| Net Cash Used in Operating Activities | $(8,172) | $(9,784) |
| Current Portion of Long-Term Debt | $3,374 | $4,333 |
Note: The Company has no commercial product revenue. Revenue is derived solely from collaboration agreements.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by approximately $1.3 million (75%) compared to Q1 2024. This was primarily due to the termination of the Ono Collaboration and Option Agreement in March 2025, which had generated significant revenue in the prior year.
- Expense Reduction: Total operating expenses decreased by $1.7 million. Research and Development (R&D) expenses dropped by $1.7 million, driven by reduced clinical trial costs for CUE-101 and CUE-102 as activities shifted to patient survival monitoring, and lower employee compensation.
- Cash Position: Cash and cash equivalents decreased by approximately $9.3 million during the quarter, reflecting ongoing operational burn and debt repayments.
- Debt Repayment: The Company repaid $1.0 million in term loans during the quarter.
Guidance, Outlook, and Risks
Subsequent Events (Post-March 31, 2025):
- Boehringer Ingelheim (BI) Collaboration: On April 10, 2025, the Company entered into a Collaboration and License Agreement with BI for CUE-501 (B cell depletion). The Company received an upfront payment of approximately $12.0 million and is eligible for up to $345.0 million in success-based milestones.
- Capital Raise: On April 14, 2025, the Company completed an underwritten public offering, receiving net proceeds of approximately $18.0 million.
- LG Chem Amendment: In March 2025, the Company regained rights to the CUE-101 program in the LG Chem territory, terminating LG Chem's rights to that specific asset.
Going Concern: The filing explicitly states that recurring losses and negative cash flows raise substantial doubt about the Company's ability to continue as a going concern within one year of the issuance date. Management estimates that existing cash, combined with the subsequent BI upfront payment and April 2025 offering proceeds, will fund operations into the second quarter of 2026. Additional capital will be required thereafter.
Market Risk: On May 12, 2025, the Company received a deficiency letter from Nasdaq regarding failure to maintain the minimum $1.00 bid price requirement. The Company has 180 days to regain compliance or face potential delisting.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the combined $30 million in subsequent proceeds (BI + Offering) against the projected burn rate to confirm the Q2 2026 liquidity timeline.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement for 10 consecutive days within the 180-day cure period to avoid delisting.
- Debt Covenants: Review the terms of the First Citizens Bank loan (due Dec 1, 2025) to ensure the Company can meet the full repayment or refinancing requirements given the current cash position.
- BI Milestone Probability: Assess the likelihood of achieving the preclinical milestones required to unlock the $345 million in potential BI payments.
- Asset Prioritization: Confirm the strategic shift in focus from the CUE-100 series (oncology) to the CUE-400/500 series (autoimmune) and the impact on R&D spending.